Results 21 to 30 of about 1,227,223 (348)

A network pharmacology-based approach to explore the active ingredients and molecular mechanism of Lei-gong-gen formula granule on a spontaneously hypertensive rat model

Chinese Medicine, 2021
Background Lei-gong-gen formula granule (LFG) is a folk prescription derived from Zhuang nationality, the largest ethnic minority among 56 nationalities in China.
Qiaofeng Li, Taijin Lan, Songhua He, Weiwei Chen, Xiaolan Li, Weiquan Zhang, Ying Liu, Qiuping Zhang, Xin Chen, Yaoyao Han, Zhiheng Su, Dan Zhu, Hongwei Guo   +12 more
doaj   +1 more source

IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation

Biomolecules & Biomedicine, 2022
Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research.
Yipeng Xu, Gabriela Pachnikova, He Wang, Yaoyao Wu, Dorothea Przybilla, Reinhold Schäfer, Zihao Chen, Shaoxing Zhu, Ulrich Keilholz   +8 more
doaj   +1 more source

Drug-Eluting Stents in Preclinical Studies [PDF]

Circulation: Cardiovascular Interventions, 2008
Coronary drug-eluting stents are commonplace in clinical practice with acceptable safety and efficacy. Preclinical evaluation of novel drug-eluting stent technologies has great importance for understanding safety and possibly efficacy of these technologies, and well-defined preclinical testing methods clearly benefit multiple communities within the ...
Keith A. Robinson, Robert L. Wilensky, Ron Waksman, Greg L. Kaluza, Elazer R. Edelman, Renu Virmani, Andrew J. Carter, Gregory J. Wilson, Juan F. Granada, Nicolas Chronos, Judah Weinberger, Robert S. Schwartz   +11 more
openaire   +3 more sources

Bayesian Framework for Multi-Source Data Integration -- Application to Human Extrapolation From Preclinical Studies [PDF]

, 2022
In preclinical investigations, e.g. in in vitro, in vivo and in silico studies, the pharmacokinetic, pharmacodynamic and toxicological characteristics of a drug are evaluated before advancing to first-in-man trial. Usually, each study is analyzed independently and the human dose range does not leverage the knowledge gained from all studies. Taking into
arxiv   +1 more source

An Evaluation of the Efficacy of Preclinical Models of Lung Cancer Drugs [PDF]

, 2020
AbstractBackgroundPreclinical cell models are the mainstay in the early stages of drug development. We sought to explore the preclinical data that differentiated successful from failed therapeutic agents in lung cancer.Methods134 failed lung cancer drugs and 27 successful lung cancer drugs were identified. Preclinical data were evaluated.
Pan, Elizabeth, Bogumil, David, Cortessis, Victoria, Yu, Sherrie, Nieva, Jorge   +4 more
openaire   +2 more sources

EO9 (Apaziquone): from the clinic to the laboratory and back again [PDF]

, 2013
EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v.
Aamdal, Adams, Bailey, Bailey, Basu, Bibby, Bibby, Burd, Butler, Cadenas, Ceelen, Choudry, Collard, Connors, Cowan, Cummings, Denny, Dirix, Ernster, Fitzsimmons, Gofrit, Hall, Hargreaves, Hay, Hay, Hay, Hendricksen, Hendricksen, Hendriks, Jain, Loadman, Lu, Maliepaard, Masters, Masters, McKeown, McLeod, Milbank, Minchinton, Oostveen, Pavlidis, Phillips, Phillips, Phillips, Phillips, Phillips, Phillips, Pizao, Plumb, Plumb, Plumb, Puri, Rademakers, Robertson, Robertson, Roed, Schellens, Segura-Aguilar, Siegel, Siegel, Smitskamp-Wilms, Stratford, Sylvester, Tercel, van der Heijden, van der Schoot, van der Schoot, van der Schoot, Vaupel, Vaupel, Walton, Walton, Workman, Workman, Workman, Zappa   +75 more
core   +1 more source

Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review [PDF]

, 2016
The positron emission tomography (PET) tracer 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) has been proposed to measure cell proliferation non-invasively in vivo. Hence, it should provide valuable information for response assessment to tumor therapies. To
Aboagye, E, Bollineni, V, Heinzmann, K, Jacobs, A, Kramer, G, Liu, Y, Schelhaas, S, Shields, A, Soloviev, D, Waterton, J   +9 more
core   +1 more source

The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development [PDF]

, 2015
Despite multiple publications on potential therapies for neuromuscular diseases (NMD) in cell and animal models only a handful reach clinical trials. The ability to prioritise drug development according to objective criteria is particularly critical in ...
Allen, Hugh, Bourke, John, Burghes, Arthur, Bushby, Kate, Buyse, Gunnar, Caizergues, Didier, Catlin, Nick, Clemens, Paula, Cnaan, Avital, Comi, Giacomo, Connor, Edward, Csimma, Cristina, Day, Simon, de Luca, Annamaria, de Montleau, Béatrice, de Visser, Marianne, Dittrich, Sven, Dubrosky, Alberto, Eagle, Michelle, Finkel, Richard, Fishbeck, Kenneth, Flanigan, Kevin M., Furlong, Patricia, Grounds, Miranda, Hauschke, Dieter, Heslop, Emma, Hesterlee, Sharon, Hoffman, Eric, Irwin, Joseph, Jarecki, Jill, Kaufmann, Petra, Kelly, Michael, Korinthenberg, Rudolf, Laforêt, Pascal, Larkindale, Jane, Lovering, Richard, Mayer, Henry, McCall, John, McDonald, Robert, McNally, Elizabeth, McNeil, Dawn Elizabeth, McNeil, Elizabeth, Mendell, Jerry, Miller, Debra, Nagaraju, Kanneboyina, North, Kathryn, Ouillade, Marie-Christine, Straub, Volker, Wagner, Kathryn R., Wells, Dominic J.   +49 more
core   +4 more sources

Ex vivo micro-computed tomography analysis of bleomycin-induced lung fibrosis for preclinical drug evaluation

European Respiratory Journal, 2013
Research into the pathogenesis underlying the development of idiopathic pulmonary fibrosis is hampered by a repertoire of animal models that fail to recapitulate all the features of the human disease.
C. Scotton, Brian Hayes, R. Alexander, Arnab Datta, E. Forty, P. Mercer, A. Blanchard, R. Chambers   +7 more
semanticscholar   +1 more source

The predictive capacity of in vitro preclinical models to evaluate drugs for the treatment of retinoblastoma

Experimental Eye Research, 2023
Retinoblastoma is a rare childhood cancer of the eye. Of the small number of drugs are used to treat retinoblastoma, all have been repurposed from drugs developed for other conditions. In order to find drugs or drug combinations better suited to the improved treatment of retinoblastoma, reliable predictive models are required, which facilitate the ...
Sinenko, Irina L., Turnell-Ritson, Roland C., Munier, Francis L., Dyson, Paul J.   +3 more
openaire   +5 more sources